ERBELLA Participates in AMUSE 2026 in Indonesia, Accelerating Expansion into the Southeast Asian Market
Writer USCarePharm
2026-06-17
[BioTimes] Medical aesthetics brand ERBELLA announced on June 17 that it participated in AMUSE 2026 (Aesthetic Medical Updates & Scientific Exhibition), an international aesthetic medicine congress held in Indonesia from June 12 to 14.
At the event, ERBELLA operated its own exhibition booth and introduced ERBELLA AQ and the ERBELLA Skin Booster Collection to local medical professionals and global buyers. Following its recent pre-launch activities in Vietnam earlier this month, ERBELLA is continuing its step-by-step global expansion strategy, with a particular focus on Southeast Asian markets including Indonesia.
Now in its third year, AMUSE is a scientific congress where aesthetic medicine professionals from various specialties, including dermatology and plastic surgery, gather to share the latest industry trends, clinical insights, and treatment techniques. Through its participation, ERBELLA expanded its engagement with regional buyers and strengthened its local business network in Indonesia’s rapidly growing medical aesthetics market.
During the congress, ERBELLA held meetings with leading Indonesian physicians and local distributors to discuss potential partnerships and distribution channel development. Following its initial product introduction through collaboration with a local partner in Vietnam, the company further broadened its regional presence through its participation in Indonesia, establishing a foundation for expansion into neighboring markets.
Moving forward, ERBELLA plans to refine its market-entry strategy for each country based on local market trends and the needs of healthcare professionals identified during the event. In addition, the company intends to develop a range of educational initiatives—including scientific exchanges with local KOLs, master classes, and hands-on workshops—to build a sustainable brand presence in Southeast Asia beyond simply supplying products.
A representative from the MA Division of USCarePharm commented:
“Following our first introduction in Vietnam, AMUSE 2026 provided an excellent opportunity to directly understand the trends of the Southeast Asian market and the needs of local healthcare professionals. We will thoroughly prepare product portfolios and educational support tailored to each country's market characteristics, with the goal of becoming a trusted global brand that grows together with our local partners.”
Source: BioTimes
Reporter: Jinju Choi (news@biotimes.co.kr)
At the event, ERBELLA operated its own exhibition booth and introduced ERBELLA AQ and the ERBELLA Skin Booster Collection to local medical professionals and global buyers. Following its recent pre-launch activities in Vietnam earlier this month, ERBELLA is continuing its step-by-step global expansion strategy, with a particular focus on Southeast Asian markets including Indonesia.
Now in its third year, AMUSE is a scientific congress where aesthetic medicine professionals from various specialties, including dermatology and plastic surgery, gather to share the latest industry trends, clinical insights, and treatment techniques. Through its participation, ERBELLA expanded its engagement with regional buyers and strengthened its local business network in Indonesia’s rapidly growing medical aesthetics market.
During the congress, ERBELLA held meetings with leading Indonesian physicians and local distributors to discuss potential partnerships and distribution channel development. Following its initial product introduction through collaboration with a local partner in Vietnam, the company further broadened its regional presence through its participation in Indonesia, establishing a foundation for expansion into neighboring markets.
Moving forward, ERBELLA plans to refine its market-entry strategy for each country based on local market trends and the needs of healthcare professionals identified during the event. In addition, the company intends to develop a range of educational initiatives—including scientific exchanges with local KOLs, master classes, and hands-on workshops—to build a sustainable brand presence in Southeast Asia beyond simply supplying products.
A representative from the MA Division of USCarePharm commented:
“Following our first introduction in Vietnam, AMUSE 2026 provided an excellent opportunity to directly understand the trends of the Southeast Asian market and the needs of local healthcare professionals. We will thoroughly prepare product portfolios and educational support tailored to each country's market characteristics, with the goal of becoming a trusted global brand that grows together with our local partners.”
Source: BioTimes
Reporter: Jinju Choi (news@biotimes.co.kr)
관련자료
-
링크
-
Next